UNSPSC 51112016: Sorafenib tosylate

This classification denotes a protein kinase inhibitor with the molecular formula C21H16ClF3N4O3.C7H8O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T62Q3B36J, chemically known as 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate), but more generally known as sorafenib tosylate, which bears US NIH Compound Identifier 216239.

European Medicines Agency schedules sorafenib tosylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23139. Sorafenib tosylate bears US NLM identifiers UMLS ID C1676709 and NCI Concept Code C2194. Most nations, for tariff purposes, schedule sorafenib tosylate under HS 29333999. SMILES: CC1CCC(CC1)S(=O)(=O)O.CNC(=O)C1CC(CCN1)OC2CCC(CC2)NC(=O)NC3CCC(C(C3)C(F)(F)F)CL.

UNSPSC 51112016 Sorafenib tosylate, a Commodity code, encompasses targeted cancer medications and specialty pharmaceuticals procured by state and local health systems, Medicaid agencies, and cooperative purchasing alliances for distribution through authorized wholesalers. State and local governments buy this code primarily as part of broader pharmaceutical procurement programs that bundle generic, multi-source, and specialty drugs for eligible patient populations across member jurisdictions. The issuing bodies are typically state Medicaid agencies, health departments, cooperative purchasing alliances serving multiple states, and county or municipal health facilities that participate in multi-state pharmaceutical contracting vehicles.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon. The contract requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Evaluation is weighted heavily on price competitiveness (75 percent), with compliance, EDI capability, and administrative fee agreements comprising the remainder. Vendors must maintain relationships with at least two of the three authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, carry $5,000,000 commercial general liability insurance, and accept performance penalties of $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions, or alignment through June 30, 2028 for incumbent vendors. No specific dollar values or set-aside designations are disclosed.